Coronary thrombolysis--it's worth the risk.
Explore this paper's citation graph
Summary
The concept of coronary thrombolysis for the treatment of acute evolving myocardial infarction has been extant for over three decades, but it is only in the last few years that profound benefits have been consistently documented in large numbers of patients.
- Type
- article
- Published
- 1989-04-14
- Cited by
- 28
- References
- 18
- OpenAlex
- https://openalex.org/W1969768448
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13213047
Keywords
Medicine, Myocardial infarction, Thrombolysis, Fibrin, Cardiology
References
- Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation.
- TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)
- LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY
- Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
- GISSI trial: early results and late follow-up. Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico.
- Ventricular function and infarct size: the Western Washington Intravenous Streptokinase in Myocardial Infarction Trial.
- Myocardial infarction and stroke
- Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival.
- Stroke after acute myocardial infarction: relation to infarct size.
- Update from the Thrombolysis in Myocardial Infarction Trial.
- Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.
- Coronary thrombolysis and myocardial salvage by tissue plasminogen activator.
- Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
- Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction.
- Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
- A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty.
- The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy.
- Spontaneous intracranial hemorrhage
Cited by
- Heparin and Streptokinase
- Acute myocardial infarction: Changing strategies in air medical transport
- Intracranial bleeding, fibrinolysis, and anticoagulation. Causal connections and clinical implications.
- An autopsy case of intracranial hemorrhage during tissue plasminogen activator infusion
- Coronary thrombolysis for the elderly?
- Thrombolysis and Myocardial Infarction
- Cost-effectiveness perspectives in coronary heart disease.
- ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early manag
- Single‐ and Double‐Chain Recombinant Tissue Plasminogen Activator: A Review of Efficacy and Safety
- Intrathecal bleeding after the intraoperative use of heparin and urokinase during continuous spinal anesthesia.
- Thrombolytic Therapy in Acute Myocardial Infarction
- Thrombolysis in venous thromboembolism. An international perspective.
- Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis.
- Incremental prognostic accuracy of clinical, radionuclide and hemodynamic data in acute myocardial infarction.
- Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
- Stroke complicating thrombolytic therapy of acute myocardial infarction.
- Coronary thrombolysis and the new biology.
- Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises.
- Guidelines for the early management of patients with acute myocardial infarction
- Thrombolytic Therapy
Related papers
- High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin.
- Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.
- Influence of alpha 2-plasmin inhibitor on adsorption of plasminogen to fibrin.
- Effect of fibrin degradation products on fibrinolytic process.
- The conversion of streptokinase-plasminogen complex to SK-plasmin complex in the presence of fibrin or fibrinogen.
- Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
- [Role of the K4 and K5 plasmin heavy chain kringles in the fibrin clot structure destruction].
- The initiation of fibrinolysis in alpha 2-plasmin inhibitor deficient plasma. Role of fibrin.